फेंटरमिन के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें फेंटरमिन (Adipex-P, Lomaira; CNS स्टिमुलेंट) के 196 इंटरैक्शन दर्ज हैं: 45 गंभीर, 113 मध्यम, 38 मामूली, और 0 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (45)

  • आइसोनियाज़िडएंटीबायोटिकगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • आइसोप्रेनालिनबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • आरफॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • इप्राट्रोपियम और सैल्बुटामोलएंटीकोलिनर्जिकगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • इमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (इमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

  • एड्रेनालिनसिम्पैथोमिमेटिकगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्फेटामाइनCNS स्टिमुलेंटगंभीर

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (एम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (एम्फेटामाइन और डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • ऑक्सीमेटाज़ोलिनडीकंजेस्टेंटगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • कोकेनलोकल एनेस्थेटिकगंभीर

    WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (कोकेन लेबल, बॉक्स्ड चेतावनी)

  • क्लोरोप्रोकेनलोकल एनेस्थेटिकगंभीर

    Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (क्लोरोप्रोकेन लेबल, चेतावनियां)

  • टरब्यूटालिनबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • टिज़ानिडिनमसल रिलैक्सेंटगंभीर

    Hypotension: monitor for signs and symptoms of hypotension, in particular in patients receiving concurrent antihypertensives; Zanaflex should not be used with other α 2 -adrenergic agonists ( 5.1 , 7.7 ) (टिज़ानिडिन लेबल, चेतावनियां और सावधानियां)

  • ट्रैनिलसाइप्रोमिनMAO इनहिबिटरगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटगंभीर

    CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. (डेक्सट्रोएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • ड्रोनाबिनोलकैनाबिनॉइडगंभीर

    Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

  • पिमोज़ाइडएंटीसाइकोटिकगंभीर

    Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. (प्रोटामिन लेबल, बॉक्स्ड चेतावनी)

  • प्रोमेथाज़िनएंटीहिस्टामिनगंभीर

    Epinephrine Because of the potential for Promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Syrup overdose. (प्रोमेथाज़िन लेबल, दवाओं के इंटरैक्शन)

  • Epinephrine – Because of the potential for promethazine to reverse epinephrine’s vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution overdose. (प्रोमेथाज़िन और डेक्सट्रोमेथॉर्फन लेबल, दवाओं के इंटरैक्शन)

  • फिनाइलएफ्रिनडीकंजेस्टेंटगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फेंटरमिन और टोपिरामेटCNS स्टिमुलेंटगंभीर

    …(8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines. (फेंटरमिन और टोपिरामेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फेनडाइमेट्राज़िनCNS स्टिमुलेंटगंभीर

    …hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other anorectic agents or CNS stimulants • Known hypersensitivity or idiosyncratic reactions to sympathomimetics (फेनडाइमेट्राज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फेनेलज़िनMAO इनहिबिटरगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फॉर्मोटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • बेंज़फेटामाइनCNS स्टिमुलेंटगंभीर

    Benzphetamine Hydrochloride Tablets should not be used concomitantly with other CNS stimulants. (बेंज़फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • मिथाइलीन ब्लूMAO इनहिबिटरगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • मिराबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • मेथएम्फेटामाइनCNS स्टिमुलेंटगंभीर

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (मेथएम्फेटामाइन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • मेपिवाकेनलोकल एनेस्थेटिकगंभीर

    Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (मेपिवाकेन लेबल, चेतावनियां)

  • यूमेक्लिडिनियम और विलैंटेरोलएंटीकोलिनर्जिकगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • रासाजिलिनMAO इनहिबिटरगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • लिनेज़ोलिडएंटीबायोटिकगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • लियोथायरोनिनथायरॉइड हार्मोनगंभीर

    • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (लियोथायरोनिन लेबल, बॉक्स्ड चेतावनी)

  • लेवोथायरोक्सिन और लियोथायरोनिनथायरॉइड हार्मोनगंभीर

    Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (लेवोथायरोक्सिन और लियोथायरोनिन लेबल, बॉक्स्ड चेतावनी)

  • लेवोसैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • विबेग्रॉनबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेलेजिलिनMAO इनहिबिटरगंभीर

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सैल्बुटामोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सैल्मेटेरोलबीटा-एड्रीनर्जिक एगोनिस्टगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सोडियम ऑक्सीबेटCNS डिप्रेसेंटगंभीर

    Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

  • स्यूडोएफेड्रिनडीकंजेस्टेंटगंभीर

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (फेंटरमिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

मध्यम इंटरैक्शन (113)

  • अल्प्राज़ोलमबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

  • आर्मोडाफिनिलCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन एस्पार्टइंसुलिनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन ग्लार्जिनइंसुलिनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन डेग्लुडेकइंसुलिनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन डेटेमिरइंसुलिनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • इंसुलिन लिस्प्रोइंसुलिनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एकार्बोज़एंटीडायबिटिक (डायबिटीज़ की दवा)मध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (एक्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

  • एक्सेनाटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एफेड्रिनसिम्पैथोमिमेटिकमध्यम

    • Pr e ssor Effect with Concomitant Oxytocic Drugs : Pressor effect of sympathomimetic pressor amines is potentiated (5.1) (एफेड्रिन लेबल, चेतावनियां और सावधानियां)

  • एमिट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    When amitriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (एमिट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

  • एमियोडेरोनएंटीएरिदमिकमध्यम

    • Hypotension: Slow the infusion; as needed, add vasopressor drugs, positive inotropic agents, and volume expansion. (एमियोडेरोन लेबल, चेतावनियां और सावधानियां)

  • एम्पाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एर्गोटामिन और कैफीनएर्गोट एल्कलॉइडमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एलोग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरमध्यम

    Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (एसिटाज़ोलामाइड लेबल, दवाओं के इंटरैक्शन)

  • एस्टाज़ोलमबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (एस्टाज़ोलम लेबल, चेतावनियां)

  • एस्मोलोलबीटा ब्लॉकरमध्यम

    Sympathomimetic drugs: Dose adjustment needed (7) (एस्मोलोल लेबल, दवाओं के इंटरैक्शन)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (एस्सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

  • ऑक्साज़ेपामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकमध्यम

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • केटामिनCNS डिप्रेसेंटमध्यम

    Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (केटामिन लेबल, चेतावनियां और सावधानियां)

  • कैंडेसार्टनएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (कैंडेसार्टन लेबल, चेतावनियां और सावधानियां)

  • कैनाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • क्लोनाज़ेपामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

  • क्लोबाज़ामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोबाज़ाम लेबल, चेतावनियां और सावधानियां)

  • क्लोमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Close supervision and careful adjustment of dosage are required when clomipramine hydrochloride capsules are administered with anticholinergic or sympathomimetic drugs. (क्लोमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

  • क्लोरडायज़ेपॉक्साइडबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

  • Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

  • क्लोराज़ेपेटबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

  • ग्लिपिज़ाइडसल्फोनिलयूरियामध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्लिपिज़ाइड और मेटफॉर्मिनसल्फोनिलयूरियामध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्लिबेनक्लामाइडसल्फोनिलयूरियामध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्लिबेनक्लामाइड और मेटफॉर्मिनसल्फोनिलयूरियामध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्लिमेपिराइडसल्फोनिलयूरियामध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्वानफेसिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (ग्वानफेसिन लेबल, चेतावनियां और सावधानियां)

  • ज़िप्रासिडोनएंटीसाइकोटिकमध्यम

    The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

  • टिमोलोलबीटा ब्लॉकरमध्यम

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (टिमोलोल लेबल, चेतावनियां और सावधानियां)

  • टियोट्रोपियमएंटीकोलिनर्जिकमध्यम

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

  • टिर्ज़ेपाटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • टेमाज़ेपामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (टेमाज़ेपाम लेबल, चेतावनियां)

  • Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (टोलकैपोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायज़ोलमबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

  • डाइएथिलप्रोपियॉनCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • डाइसाइक्लोमिनएंटीकोलिनर्जिकमध्यम

    …drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

  • डायज़ेपामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

  • डिगॉक्सिनडिजिटेलिस ग्लाइकोसाइडमध्यम

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (डिगॉक्सिन लेबल, दवाओं के इंटरैक्शन)

  • डुलाग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (डुलोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • डेक्समिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (डेसवेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

  • डेसिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs. (डेसिप्रामिन लेबल, दवाओं के इंटरैक्शन)

  • डैपाग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (डॉक्साप्राम लेबल, दवाओं के इंटरैक्शन)

  • डोरज़ोलामाइड और टिमोलोलकार्बोनिक एनहाइड्रेज़ इनहिबिटरमध्यम

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

  • नाल्ट्रेक्सोन और ब्यूप्रोपियॉनओपिओइड एंटागोनिस्टमध्यम

    …tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides) that may cause hypoglycemia concomitant… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

  • नेटेग्लिनाइडमेग्लिटिनाइडमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • नॉरट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (नॉरट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

  • पियोग्लिटाज़ोनथायज़ोलिडिनडायोनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • पियोग्लिटाज़ोन और ग्लिमेपिराइडथायज़ोलिडिनडायोनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • पियोग्लिटाज़ोन और मेटफॉर्मिनथायज़ोलिडिनडायोनमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (पैरोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • प्रोट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटमध्यम

    Drug Interactions When protriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (प्रोट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

  • प्रोप्रानोलोलबीटा ब्लॉकरमध्यम

    Pharmacodynamic Drug-Drug Interactions Adrenergic Agonists: Beta-blockers may antagonize the antihypertensive effects of clonidine, and rebound hypertension may result if clonidine is withdrawn abruptly. (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

  • बेक्साग्लिफ्लोज़िनSGLT2 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (बोर्टेज़ोमिब लेबल, चेतावनियां और सावधानियां)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ब्यूप्रोपियॉनएंटीडिप्रेसेंटमध्यम

    …medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse of prescription drugs such as CNS stimulants. (ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

  • ब्रिमोनिडिन और टिमोलोलअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (ब्रिमोनिडिन और टिमोलोल लेबल, चेतावनियां और सावधानियां)

  • मिग्लिटोलएंटीडायबिटिक (डायबिटीज़ की दवा)मध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • मिथाइलडोपाएंटीहाइपरटेंसिव (ब्लड प्रेशर की दवा)मध्यम

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (मिथाइलडोपा लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलफेनिडेटCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • मिर्टाज़ापिनएंटीडिप्रेसेंटमध्यम

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (मिर्टाज़ापिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

  • मेटफॉर्मिनबाइगुआनाइडमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकमध्यम

    Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (मेटोलाज़ोन लेबल, दवाओं के इंटरैक्शन)

  • मोडाफिनिलCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • रिटोनाविरएंटीरेट्रोवायरलमध्यम

    Anesthetic: meperidine ↓ meperidine/ ↑ normeperidine (metabolite) Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures). (रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • रेपाग्लिनाइडमेग्लिटिनाइडमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • लिडोकेनलोकल एनेस्थेटिकमध्यम

    Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (लिडोकेन लेबल, दवाओं के इंटरैक्शन)

  • लिनाग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • लिराग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • लिसडेक्सएम्फेटामाइनCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • लेवोथायरोक्सिनथायरॉइड हार्मोनमध्यम

    Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (लेवोमिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

  • लोराज़ेपामबेंज़ोडायज़ेपिनमध्यम

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (विलाज़ोडोन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (वेनलाफैक्सिन लेबल, चेतावनियां और सावधानियां)

  • वोर्टियोक्सेटिनएंटीडिप्रेसेंटमध्यम

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (वोर्टियोक्सेटिन लेबल, चेतावनियां और सावधानियां)

  • शराब (अल्कोहल)शराब (अल्कोहल)मध्यम

    • Concomitant alcohol use may result in an adverse drug reaction. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (सर्ट्रालिन लेबल, चेतावनियां और सावधानियां)

  • Circulatory Shock Circulatory shock with fever, severe hypotension, and confusion requiring intravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge with trimethoprim-sulfamethoxazole products in patients with history of recent (days to weeks) exposure to sulfamethoxazole and trimethoprim. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, चेतावनियां)

  • सिटाग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

  • The most commonly described clinical features in reports of anaphylaxis were dermatologic symptoms (including urticaria, rash, erythema, flushing and skin eruption); and clinically important hypotension often requiring the use of vasopressors for circulatory support. (सुगैमाडेक्स लेबल, चेतावनियां और सावधानियां)

  • सेमाग्लूटाइडGLP-1 रिसेप्टर एगोनिस्टमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • सैक्साग्लिप्टिनDPP-4 इनहिबिटरमध्यम

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • सोटालोलबीटा ब्लॉकरमध्यम

    Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (सोटालोल लेबल, दवाओं के इंटरैक्शन)

  • सोलरियमफेटोलCNS स्टिमुलेंटमध्यम

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

मामूली ज़िक्र (38)

  • अमैंटाडिनएंटीकोलिनर्जिकमामूली

    Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (अमैंटाडिन लेबल, दवाओं के इंटरैक्शन)

  • इप्राट्रोपियमएंटीकोलिनर्जिकमामूली

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (इप्राट्रोपियम लेबल, दवाओं के इंटरैक्शन)

  • एमोक्सापिनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एलेट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एल्मोट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • एसिब्यूटोलोलबीटा ब्लॉकरमामूली

    A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (एसिब्यूटोलोल लेबल, चेतावनियां)

  • ओन्डैनसेट्रॉनQT अंतराल बढ़ाने वाली दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ग्रैनिसेट्रॉनQT अंतराल बढ़ाने वाली दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ज़ोल्मिट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • टियागाबिनएंटीकन्वल्सेंट (दौरे की दवा)मामूली

    In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

  • टेपेंटाडोलओपिओइडमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ट्राइमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ट्रामाडोलओपिओइडमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • ट्रैज़ोडोनएंटीडिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • डाइहाइड्रोएर्गोटामिनएर्गोट एल्कलॉइडमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • डेक्सट्रोमेथॉर्फनसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • डेक्सट्रोमेथॉर्फन और क्विनिडिनसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • डॉक्सेपिनट्राइसाइक्लिक एंटीडिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • नाराट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • नेफाज़ोडोनएंटीडिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • परफेनाज़िनएंटीसाइकोटिकमामूली

    If a vasopressor is needed, norepinephrine may be used. (परफेनाज़िन लेबल, चेतावनियां)

  • पेथिडीनओपिओइडमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • पैलोनोसेट्रॉनसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • प्रुकालोप्राइडसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • प्रोपोफोलCNS डिप्रेसेंटमामूली

    These effects are responsive to discontinuation of DIPRIVAN, intravenous fluid administration, and/or vasopressor therapy. (प्रोपोफोल लेबल, चेतावनियां और सावधानियां)

  • फ्रोवाट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • फ्लिबैनसेरिनCNS डिप्रेसेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • बस्पिरोनसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • Severe reactions have required intervention with vasopressor agents and supportive measures. (बेंज़ोनाटेट लेबल, चेतावनियां)

  • ब्रोमोक्रिप्टिनडोपामिन एगोनिस्टमामूली

    There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

  • रिज़ाट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • रैमेल्टियॉनसेडेटिव-हिप्नोटिक (नींद की दवा)मामूली

    In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (रैमेल्टियॉन लेबल, चेतावनियां और सावधानियां)

  • लिथियमसेरोटोनर्जिक दवामामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • लेबेटालोलबीटा ब्लॉकरमामूली

    Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. (लेबेटालोल लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोबेंज़ाप्रिनमसल रिलैक्सेंटमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • सुमाट्रिप्टानट्रिप्टानमामूली

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

  • The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

आप जो कुछ भी लेते हैं, उस सबके साथ फेंटरमिन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।